GlassScriptPhysician profile
Ryan Alan Schuering
NPI 1942684568
$3,016.11
in general payments reported to CMS, 2019-2025
21 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $88.26 · 2021: $222 · 2022: $162 · 2023: $365 · 2024: $590 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.04 | 2019-2024 | |
| Janssen Biotech, INC. | $361.67 | 2020-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $343.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $258.08 | 2019-2024 | Dupixent |
| Allergan, INC. | $244.56 | 2019 | |
| Merz North America, INC. | $240.16 | 2022-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $176.94 | 2022-2025 | Blu-U, Odomzo |
| Celgene Corporation | $125.02 | 2019 | |
| Dova Pharmaceuticals | $124.87 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $97.54 | 2021 | |
| Galderma Laboratories, L.P. | $80.09 | 2020-2024 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Almirall LLC | $61.80 | 2023-2025 | Klisyri, Seysara |
| Genzyme Corporation | $36.33 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.89 | 2019-2022 | |
| Strata Skin Sciences, INC. | $24.07 | 2025 | Xtrac |
| Incyte Corporation | $23.90 | 2024 | Opzelura |
| Amgen INC. | $21.93 | 2024 | Otezla |
| Icad, INC | $14.57 | 2022 | |
| Mayne Pharma Commercial LLC | $9.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Schuering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.